skip to Main Content

Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197

Fina Biosolutions has selected Scorpius BioManufacturing, a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM197conjugate vaccine carrier protein.

The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, scale-up, and cGMP bulk drug substance manufacturing of CRM197, a genetically detoxified diphtheria toxin widely used in conjugate vaccines. FinaBio markets their CRM197 under the tradename EcoCRM®.

Read complete press release.

Please enter your details to download the PDF